Nathan Rice

Stock Analyst at Piper Sandler

(3.10)
# 1,129
Out of 5,170 analysts
61
Total ratings
52.63%
Success rate
10.65%
Average return

Stocks Rated by Nathan Rice

Bank First
Jan 26, 2026
Maintains: Neutral
Price Target: $142$150
Current: $134.23
Upside: +11.75%
First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49$48
Current: $39.62
Upside: +21.15%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $41.76
Upside: +0.57%
Byline Bancorp
Oct 28, 2025
Maintains: Overweight
Price Target: $34$35
Current: $30.39
Upside: +15.17%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $71.86
Upside: +2.98%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $141.50
Upside: -40.64%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $176.25
Upside: +11.77%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $25.12
Upside: -64.17%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $579.85
Upside: -24.98%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $264.57
Upside: -11.93%
Initiates: Neutral
Price Target: $83
Current: $35.57
Upside: +133.34%
Initiates: Overweight
Price Target: $15
Current: $19.58
Upside: -23.39%